^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:HER2 Negative Breast Cancer
    Drug:everolimus (mTOR inhibitor) +
    Verzenio (abemaciclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Clin Oncol
    Title:

    A phase Ib study of abemaciclib with therapies for metastatic breast cancer.

    Excerpt:
    Patients (pts) in 6 cohorts received abemaciclib 150-200 mg every 12 hours (Q12H) with letrozole 2.5 mg/d (Part A), anastrozole 1 mg/d (Part B), tamoxifen 20 mg/d (Part C), exemestane 25 mg/d (Part D), exemestane 25 mg/d + everolimus 5 mg/d (Part E)...Combinations of abemaciclib with endocrine therapies demonstrate manageable safety and early clinical evidence of antitumor activity.
    Secondary therapy:
    exemestane
    DOI:
    10.1200/jco.2015.33.15_suppl.522